HaemaLogiX Honored for Promising CAR-T Pipeline in Asia Pacific

HaemaLogiX Recognized as Industry Leader in CAR-T Therapy

On September 10, 2025, HaemaLogiX Ltd, an innovative Australian biotech firm specializing in immunotherapies, was awarded the title of 'Most Promising CAR-T Pipeline in APAC' at the Asia Pacific CGT Excellence Awards held in Singapore. This prestigious accolade acknowledges the company’s remarkable contributions to the field of CAR-T therapy, particularly for patients suffering from blood cancers such as multiple myeloma.

An Award of Distinction

The Asia Pacific CGT Excellence Awards highlight companies at the forefront of innovation in cellular and gene therapies. HaemaLogiX's achievement is a clear testament to its commitment to pushing the boundaries of what is possible in CAR-T treatment. The company is recognized for its dedication to improving therapeutic outcomes for patients and advancing research in the rapidly evolving field of oncology.

Professor Rosanne Dunn, the founder and Chief Scientific Officer of HaemaLogiX, expressed her gratitude upon receiving the award: "This recognition is a validation of our relentless pursuit to innovate and refine cancer care. We are proud to stand alongside other top innovators in the region, all working towards redefining the standard of care in CAR-T therapies. Our focus remains on developing transformative treatments for multiple myeloma, which currently lacks a definitive cure."

Breakthrough Immunotherapies

HaemaLogiX is developing immunotherapy treatments that specifically target unique antigens found on the surface of malignant plasma cells. Their therapies focus on kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA), which distinguish malignant cells from healthy ones. This targeted approach reduces off-tumor effects and preserves the immune system’s integrity, representing a significant improvement over existing treatment options.

Interestingly, studies suggest that around 70% of multiple myeloma cases express KMA while 30% express LMA, indicating a clear pathway for personalized treatment strategies. This tailored approach not only enhances efficacy but also minimizes adverse effects, providing patients with a new hope in their fight against cancer.

The Challenge of Multiple Myeloma

Multiple myeloma ranks as the second most prevalent blood cancer worldwide, with approximately 188,000 new cases diagnosed each year. Tragically, about 60% of patients do not respond well to standard therapies and find themselves relying on subsequent treatments, which often yield diminishing results. Alarmingly, nearly 42% of individuals diagnosed with multiple myeloma do not survive beyond five years. These sobering statistics underline a significant unmet medical need and emphasize the urgency for new, safer, and more effective treatment options.

HaemaLogiX's pioneering therapies are poised to fill this gap, offering more effective solutions to enhance patient quality of life and potentially improve survival rates.

The Road Ahead

With its recent recognition at the Asia Pacific CGT Excellence Awards, HaemaLogiX solidifies its position as a trailblazer in the development of CAR-T therapies. The company's vision aligns with the growing demand for advanced and precise cancer treatment modalities, driven by an unwavering commitment to scientific excellence and patient outcomes.

As the biotechnology landscape evolves, HaemaLogiX is committed to leading the charge in CAR-T therapy innovation, ultimately aiming to transform the future of cancer treatment for countless patients in the Asia Pacific region and beyond.

Through its relentless pursuit of groundbreaking therapies and unyielding focus on patient care, HaemaLogiX is proving to be a beacon of hope for those battling blood cancers, especially for patients grappling with the complexities of multiple myeloma.